NeoDynamics newsletter April 2022
NeoDynamics' sales focus in the first half of 2022
Innovation is at the heart of everything we do at NeoDynamics and no better evidence of that can be seen in our FlexiPulse needle. Developed by physicians, with the goal to improve how biopsies are performed. FlexiPulse features a unique open-tip, large sampling chamber and these attributes combined with our patented pulse technology, allow for large, high-quality tissue samples to be taken from places generally considered to be difficult to access.
We continue to gather extremely valuable clinical experience and data with FlexiPulse and the results from our PULSE study showed fantastic benefit in many complex, high risk cases, such as procedures close to nerves and blood vessels.
With excellent data to support our sales efforts, our focus is on demonstrating the benefits of our innovative FlexiPulse needle. This area is the key to physicians understand the technology, it’s development and have the proper chance to get to experience it.
In the UK we are currently working closely with Wycombe, Cheltenham and Edinburgh hospitals with another 18 centers in the pipeline to start evaluating NeoNavia this year. In the German-speaking part of Europe, NeoNavia is already present in Erkelenz, Lucerne, Cologne and evaluations are ongoing in 13 centers. In addition, we now have an oral presentation of our PULSE data in Savannah Georgia in May - among purely American research results there is thus a Swedish innovation and its clinical results will be presented. Axillary lymph nodes in the armpit and axillary biopsies are "hot" topics these days!
The Western General breast unit in Edinburgh is one of the centers participating in our COMPULSE study. Here, senior radiologist Dr. Melanie Smith, comments on her experience of NeoDynamics' innovative Pulse Biopsy System, NeoNavia.
FlexiPulse – an open-tip, front-loaded needle
The FlexiPulse needle is intended for ultrasound-guided breast biopsy and particularly well suited for technically challenging biopsies such as in axillary lymph nodes and dense breast tissue. This needle has been specifically developed to maximise tissue yield whilst causing the least possible damage to surrounding tissue. In pre-clinical studies, the FlexiPulse needle has provided larger samples than current core needles.
Design and features:
Did you know...
Global Breast Biopsy Market is valued at $725 million in 2020, and is projected to reach at $1,094 million by 2025, growing at a CAGR of 8.6% from 2020 to 2025.
Subscribe to this Newsletter - register here!
In our next newsletter, you will hear Professor Marc Thill talk about his experiences with NeoNavia and read more about our participation in the American SBI/ACR congress in Savannah in May.